The Infectious Diseases Clinical Research Consortium has begun enrolling up to 1,000 pregnant and postpartum individuals who have or will receive COVID-19 vaccine in a study to assess vaccine safety, immune response and transfer of antibodies to their infants, the National Institutes of Health announced yesterday. The study will enroll individuals up to two months postpartum, and follow participants and their infants through the first year after delivery.

“Tens of thousands of pregnant and breastfeeding people in the United States have chosen to receive the COVID-19 vaccines available under emergency use authorization,” said Anthony Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases “However, we lack robust, prospective clinical data on vaccination in these populations. The results of this study will fill gaps in our knowledge and help inform policy recommendations and personal decision-making on COVID-19 vaccination during pregnancy and in the postpartum period.”
 

Related News Articles

Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…
Headline
The American College of Obstetricians and Gynecologists April 17 released guidance recommending a new approach to prenatal care delivery. The guidance calls…
Headline
The National Institutes of Health April 7 released a study that found twins — smaller at birth on average than singletons — develop slower in early pregnancy…
Headline
A National Institutes of Health study published April 2 found that blood pressure patterns observed during the first half of pregnancy can determine a woman's…
Headline
The U.S. birth rate fell 2% in 2023 to about 3.6 million, according to final data released March 18 by the Centers for Disease Control and Prevention. The…
Headline
A study by the Penn State Department of Nutritional Sciences found that low vitamin D levels in the first trimester of pregnancy are associated with higher…